Applied UV Inc., of Mount Vernon, N.Y., said it has signed a nonbinding letter of intent to explore the possibility of acquiring certain assets of Akida Holdings LLC, of Jacksonville, Fla., including Akida’s rights to the manufacture and sale of the Airocide system of air purification technologies. In September, Applied UV and Akida announced an exclusive joint distribution and licensing agreement.

Apyx Medical Corp., of Clearwater, Fla., said it has completed enrollment in an IDE clinical trial evaluating the use of its Renuvion technology in dermal resurfacing procedures. Additionally, the company reported that the U.S. FDA concluded that the requirements were met for its safety report for the phase I feasibility study of the IDE study assessing Renuvion’s use in skin laxity procedures in the neck and submental region.

Cleveland Clinic and Epic Corp., of Verona, Wis., said a COVID-19 risk prediction model designed by Cleveland Clinic researchers is now available to health systems worldwide through Epic. Developed and tested using clinical data rom more than 11,000 Cleveland Clinic patients, the model uses information from patients’ comprehensive health records combines with patient-entered information in Epic’s patient-facing app, Mychart, to show an individual’s likelihood of testing positive for COVID-19.

Concept Medical Inc., of Tampa, Fla., reported the first patient enrolled in its SirPAD (Sirolimus in Peripheral Artery Disease) trial. SirPAD is the first all-comer randomized, controlled study investigating major adverse limb events in PAD patients with lesions below the inguinal ligament. The investigator-initiated, single center, randomized, noninferiority, open-label trial is evaluating whether the use of Magictouch PTA (percutaneous transluminal angioplasty) sirolimus-coated balloon catheters in patients with PAD of the femoro-popliteal or below-the-knee segment is not inferior to that of uncoated balloon catheters for major clinical outcomes (unplanned major amputation or target limb revascularization). A total of 1,200 patients will be randomized 1:1 in the study.

Hong Kong-based Orbusneich Medical Co. Ltd. and P+F Products + Features GmbH, of Vienna, Austria, have entered an agreement for the exclusive distribution and manufacturing of a range of minimally invasive heart valve products in the Asia Pacific region, including China, Japan, Taiwan, South Korea, Hong Kong, Singapore, Malaysia, Australia and New Zealand.

Protec Scientific Inc., of Utica, N.Y., reported the launch of Protec 99, a battery-operated, hand-held ultraviolet-C sterilization device with a 99.99% germicidal rating, to combat viruses and bacterial pathogens, including influenza and COVID-19.